These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 697826)

  • 1. Stereochemistry of dihydrofolate reductase inhibitor antitumor agents: molecular structure of "Baker's antifol" (NSC 139105, triazinate) and "insoluble Baker's antifol" (NSC 113423).
    Camerman A; Smith HW; Camerman N
    Biochem Biophys Res Commun; 1978 Jul; 83(1):87-93. PubMed ID: 697826
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.
    Bruckner HW; Lokich JJ; Stablein DM
    Cancer Treat Rep; 1982 Sep; 66(9):1713-7. PubMed ID: 7116348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I studies with Baker's Antifol (BAF) (NSC 139105).
    Rodriguez V; Gottlieb J; Burgess MA; Livingston R; Wheeler W; Spitzer G; Bodey GP; Blumenschein GR; Freireich EJ
    Cancer; 1976 Aug; 38(2):690-4. PubMed ID: 974989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study.
    Arseneau JC; Bundy B; Homesley H; Beecham J
    Invest New Drugs; 1983; 1(2):185-8. PubMed ID: 6236163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
    Mini E; Moroson BA; Franco CT; Bertino JR
    Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of Baker's antifol (triazinate, TZT, NSC-139,105) in advanced squamous cell carcinoma of cervix.
    Arseneau JC; Bundy B; Dolan T; Homesley H; DiSaia PJ
    Am J Clin Oncol; 1982 Feb; 5(1):61-4. PubMed ID: 6211087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DNA synthesis in normal and malignant human cells by triazinate (Baker's antifol) and methotrexate.
    Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
    Cancer Res; 1976 Oct; 36(10):3659-64. PubMed ID: 953990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.
    Kalghatgi KK; Moroson BA; Horváth C; Bertino JR
    Cancer Res; 1979 Sep; 39(9):3441-5. PubMed ID: 476673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study with Baker's Antifol in solid tumors.
    Rodriguez V; Richman SP; Benjamin RS; Burgess MA; Murphy WK; Valdivieso M; Banner RL; Gutterman JU; Bodey GP; Freireich EJ
    Cancer Res; 1977 Apr; 37(4):980-3. PubMed ID: 139205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baker's antifol in children with late-stage acute lymphocytic leukemia.
    Nitschke R; Vietti T; Ragab A; Dyment P
    Cancer Treat Rep; 1978 Dec; 62(12):2109-10. PubMed ID: 376130
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer.
    Krasnow S; Green M; Perry DJ; Eisenberger MA; Johnston-Early A; Muggia F; Cohen MH
    Cancer Treat Rep; 1986 Aug; 70(8):1039-40. PubMed ID: 3524834
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in man.
    Loo TL; Benjamin RS; Lu K; Benvenuto JA; Hall SW; McKelvey EM
    Drug Metab Rev; 1978; 8(1):137-50. PubMed ID: 363378
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma.
    McCreary RH; Moertel CG; Schutt AJ; O'Connell MJ; Hahn RG; Reitemeier RJ; Rubin J; Frytak S
    Cancer; 1977 Jul; 40(1):9-13. PubMed ID: 141977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acanthosis nigricans-like hyperpigmentation secondary to triazinate therapy.
    Greenspan AH; Shupack JL; Foo SH; Wise AC
    Arch Dermatol; 1985 Feb; 121(2):232-5. PubMed ID: 3977338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of Baker's antifol in advanced colorectal cancer.
    Padilla F; Correa J; Buroker T; Vaitkevicius VK
    Cancer Treat Rep; 1978 Apr; 62(4):553-4. PubMed ID: 350391
    [No Abstract]   [Full Text] [Related]  

  • 16. Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group Study (Protocol 7764).
    Shaw MT; Bonnet JD; Wilson H; Heilbrun LK
    Cancer Treat Rep; 1980; 64(2-3):247-50. PubMed ID: 7407758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.
    Chello PL; McQueen CA; DeAngelis LM; Bertino JR
    Cancer Res; 1976 Jul; 36(7 PT 1):2442-9. PubMed ID: 1277151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined distance geometry analysis of dihydrofolate reductase inhibition by quinazolines and triazines.
    Ghose AK; Crippen GM
    J Med Chem; 1983 Jul; 26(7):996-1010. PubMed ID: 6864738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study.
    Bukowski RM; LoBuglio A; McCracken J; Pugh R
    Cancer Treat Rep; 1980; 64(12):1387-8. PubMed ID: 7471126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, in vitro antitumor activity, dihydrofolate reductase inhibition, DNA intercalation and structure-activity relationship studies of 1,3,5-triazine analogues.
    Singla P; Luxami V; Paul K
    Bioorg Med Chem Lett; 2016 Jan; 26(2):518-523. PubMed ID: 26670841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.